TY - JOUR
T1 - Minimally Invasive vs Conventional Aortic Valve Replacement With Rapid-Deployment Bioprostheses
AU - D'Onofrio, Augusto
AU - Tessari, Chiara
AU - Lorenzoni, Giulia
AU - Lorenzoni, Gianni
AU - Cibin, Giorgia
AU - Martinelli, Gianluca
AU - Alamanni, Francesco
AU - Polvani, Gianluca
AU - Solinas, Marco
AU - Massetti, Massimo
AU - Merlo, Maurizio
AU - Vendramin, Igor
AU - Di Eusanio, Marco
AU - Mignosa, Carmelo
AU - Mangino, Domenico
AU - Russo, Claudio
AU - Rinaldi, Mauro
AU - Pacini, Davide
AU - Salvador, Loris
AU - Antona, Carlo
AU - Maselli, Daniele
AU - De Paulis, Ruggero
AU - Luzi, Giampaolo
AU - Alfieri, Ottavio
AU - De Filippo, Carlo Maria
AU - Portoghese, Michele
AU - Portoghese, Luca Michele
AU - Musumeci, Francesco
AU - Colli, Andrea
AU - Gregori, Dario
AU - Gerosa, Gino
PY - 2021
Y1 - 2021
N2 - Background: The aim of this multicenter retrospective study was to compare early and midterm clinical and hemodynamic results of aortic valve replacement with rapid-deployment bioprostheses performed through conventional full-sternotomy vs mini-sternotomy. Methods: Data from the Italian multicenter registry of aortic valve replacement with rapid-deployment bioprostheses (INTU-ITA registry) were analyzed. Patients were divided into 2 groups: full sternotomy (FS) and ministernotomy (MS). Primary endpoint was the comparison of early and midterm mortality. Secondary endpoints were: comparison of intraoperative variables, complications, and hemodynamic performance. A propensity score weighting approach was used for data analysis. Results: A total of 1057 patients were analyzed: 435 (41.2%) and 622 (58.8%) in group FS and MS, respectively. Thirty-day mortality was 1.6% and 0.6% in FS and MS groups, respectively (P =.074). cardiopulmonary bypass time was 78.5 minutes and 83 minutes in FS and MS groups, respectively (P =.414). In the overall cohort, the incidence of intraoperative complications and of device success was 3.8% (40 patients) and 95.9% (1014 patients), respectively, with no significant differences between groups. Survival at 1, 3, and 5 years was 94.1%, 98.1%, 88.5% and 91.8%, 85.2%, and 84.8% in FS and MS groups, respectively (P =.412). The 2 groups showed similar postoperative gradients (median mean gradient, FS: 10.0 mm Hg, MS: 11.0 mm Hg; P =.170) and also similar incidence of patient–prosthesis mismatch (FS: 7%, MS: 6.4%, P =.647). Conclusions: According to our data, rapid-deployment bioprostheses allow the performance of minimally invasive aortic valve replacement with similar surgical times and similar clinical and hemodynamic outcomes to conventional surgery and should be considered the first choice in these procedures.
AB - Background: The aim of this multicenter retrospective study was to compare early and midterm clinical and hemodynamic results of aortic valve replacement with rapid-deployment bioprostheses performed through conventional full-sternotomy vs mini-sternotomy. Methods: Data from the Italian multicenter registry of aortic valve replacement with rapid-deployment bioprostheses (INTU-ITA registry) were analyzed. Patients were divided into 2 groups: full sternotomy (FS) and ministernotomy (MS). Primary endpoint was the comparison of early and midterm mortality. Secondary endpoints were: comparison of intraoperative variables, complications, and hemodynamic performance. A propensity score weighting approach was used for data analysis. Results: A total of 1057 patients were analyzed: 435 (41.2%) and 622 (58.8%) in group FS and MS, respectively. Thirty-day mortality was 1.6% and 0.6% in FS and MS groups, respectively (P =.074). cardiopulmonary bypass time was 78.5 minutes and 83 minutes in FS and MS groups, respectively (P =.414). In the overall cohort, the incidence of intraoperative complications and of device success was 3.8% (40 patients) and 95.9% (1014 patients), respectively, with no significant differences between groups. Survival at 1, 3, and 5 years was 94.1%, 98.1%, 88.5% and 91.8%, 85.2%, and 84.8% in FS and MS groups, respectively (P =.412). The 2 groups showed similar postoperative gradients (median mean gradient, FS: 10.0 mm Hg, MS: 11.0 mm Hg; P =.170) and also similar incidence of patient–prosthesis mismatch (FS: 7%, MS: 6.4%, P =.647). Conclusions: According to our data, rapid-deployment bioprostheses allow the performance of minimally invasive aortic valve replacement with similar surgical times and similar clinical and hemodynamic outcomes to conventional surgery and should be considered the first choice in these procedures.
KW - Aged
KW - Aortic Valve Stenosis
KW - Bioprosthesis
KW - Female
KW - Heart Valve Prosthesis
KW - Heart Valve Prosthesis Implantation
KW - Humans
KW - Italy
KW - Male
KW - Minimally Invasive Surgical Procedures
KW - Operative Time
KW - Postoperative Complications
KW - Propensity Score
KW - Registries
KW - Retrospective Studies
KW - Sternotomy
KW - Survival Rate
KW - Treatment Outcome
KW - Aged
KW - Aortic Valve Stenosis
KW - Bioprosthesis
KW - Female
KW - Heart Valve Prosthesis
KW - Heart Valve Prosthesis Implantation
KW - Humans
KW - Italy
KW - Male
KW - Minimally Invasive Surgical Procedures
KW - Operative Time
KW - Postoperative Complications
KW - Propensity Score
KW - Registries
KW - Retrospective Studies
KW - Sternotomy
KW - Survival Rate
KW - Treatment Outcome
UR - http://hdl.handle.net/10807/199104
U2 - 10.1016/j.athoracsur.2020.06.150
DO - 10.1016/j.athoracsur.2020.06.150
M3 - Article
SN - 0003-4975
VL - 111
SP - 1916
EP - 1922
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
ER -